94 search results for: chronic inflammation

Inside the Hive: Type 2 Inflammatory Pathways in <b>Chronic</b> Spontaneous Urticaria

expert video

Inside the Hive: Type 2 Inflammatory Pathways in Chronic Spontaneous Urticaria

16 min

Dermatology

Join Dr. Jason Hawkes in discussing the burden of CSU and how type 2 inflammation contributes to the development of chronic wheals (hives) and angioedema

The Heterogeneity of Underlying <b>Inflammation</b> in Patients With COPD

expert video

The Heterogeneity of Underlying Inflammation in Patients With COPD

2 min

Pulmonology

Join global expert Professor Ian Pavord as he discusses the heterogeneity of underlying inflammation in patients with COPD.

Emerging Understanding of <b>Chronic</b> Itchy Skin Diseases: Shared and Unique Drivers in AD, PN, and CSU

expert video

Emerging Understanding of Chronic Itchy Skin Diseases: Shared and Unique Drivers in AD, PN, and CSU

68 min

Dermatology

Review the roles of type 2 inflammation in the skin manifestations and itch in these chronic skin conditions.

ERS 2024 | Living With COPD: Linking <b>Inflammation</b> with Patient Burden

expert video

ERS 2024 | Living With COPD: Linking Inflammation with Patient Burden

15 min

Pulmonology

Professor Henrik Watz explores the complex relationship between inflammation and COPD, highlighting its impact on patients' health and overall quality of life.

The Role of Type 2 <b>Inflammation</b> in Atopic Dermatitis

expert video

The Role of Type 2 Inflammation in Atopic Dermatitis

1 min

Dermatology

The impact of type 2 inflammation and barrier dysfunction in the pathogenesis of chronic disease in atopic dermatitis.

<b>Chronic</b> Obstructive Pulmonary Disease: Disease Burden & Heterogeneity

interactivity

Chronic Obstructive Pulmonary Disease: Disease Burden & Heterogeneity

5 min

Pulmonology

Learn about the disease burden and heterogeneity of chronic obstructive pulmonary disease (COPD).

interactivity

Understanding IL-33: A Key Factor in COPD Pathogenesis

5 min

Pulmonology

Explore the role of interleukin (IL)-33 in chronic obstructive pulmonary disease (COPD) pathophysiology and its potential as a therapeutic target.

expert video

UEGW 2024 | WHY Is Long-Term Management of EoE Important?

10 min

Gastroenterology

Prof. Salvatore Oliva discusses the impact of chronic type 2 inflammation on EoE progression, highlighting the need for long-term management.

Infographic

Emerging Understanding of Chronic Itchy Skin Diseases – Shared and Unique Drivers in AD, PN, and CSU

5 min

Dermatology

An infographic summarizing the shared and distinct features of AD, PN, and CSU that are driven by type 2 inflammation.

What Drives <b>Chronic</b> Itch and the Itch-Scratch Cycle in Atopic Dermatitis?

videoanimation

What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?

6 min

Dermatology

Watch this short video to learn how type 2 inflammation, skin barrier dysfunction, and neurosensitization contribute to chronic itch and the itch-scratch cycle in atopic dermatitis

Why targeting Type 2 <b>Inflammation</b> is important in the treatment of skin diseases like AD, PN and CSU

expert video

Why targeting Type 2 Inflammation is important in the treatment of skin diseases like AD, PN and CSU

5 min

Dermatology

Dr. Palomares discusses how type 2 inflammation, an aberrant immune response, underlies skin diseases like atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria, linking to their clinical symptoms.

Itch in AD, PN and CSU: Role of Type 2 <b>Inflammation</b>

expert video

Itch in AD, PN and CSU: Role of Type 2 Inflammation

27 min

Dermatology

Review the role of type 2 inflammation in the skin manifestations and itch in these chronic skin conditions.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: BrazilChange country/region